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Abstract: Th   e hallmark of Parkinson’s disease is on-going degeneration of dopaminergic neurons in the substantia nigra, which 
may be due to various etiologies. Various approaches to alleviate symptoms are available, such as life-long pharmacological 
intervention, deep brain stimulation, and transplantation of dopaminergic neuron-containing fetal tissue. However, each of 
these approaches has a disadvantage. Several studies have shown that various kinds of stem cells, induced pluripotent stem cells, 
and other cells can diff  erentiate into dopaminergic neurons and may be promising for treating Parkinson’s disease in the future. 
Th   erefore, this review addresses those cells in terms of their prospects in cell therapy for Parkinson’s disease. In addition, the 
need for safety and effi   cacy studies, various cell delivery modes and sites, and possible side eff  ects will be discussed.
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toms in some advanced cases [3-5].
As the main cause of symptoms is on-going degeneration, 
attempts to stop degeneration using neuroprotective ag-
ents such as glial cell-line derived neurotrophic factor 
(GDNF) have been conducted and show promising results, 
although side effects due to off-target responses might 
appear [6]. Furthermore, the use of cannabinoids to protect 
dopaminergic neurons may be promising, but further studies 
are needed to reveal the exact mechanism of action [7]. 
Th   erefore, the best approach might be replacement of the 
degenerated neurons. Before the stem cell era, replacement 
therapy, which used dopaminergic neuron-containing 
fetal tissue that was transplanted into the brain, showed 
variable results [8, 9] due to the inability to standardize 
the transplanted cells. Moreover, tissue availability is also a 
problem [10].
Advances in stem cell research have opened a new cell 
therapy era for Parkinson’s disease. Therefore, this review 
addresses the various kinds of stem cells and other cells 
that may be suitable for cell therapy, cells requirements for 
transplant, various cell delivery modes and sites, the possible 
side eff  ects that may arise, and the need for safety and effi   cacy 
studies before application of cell therapy to patients with 
Parkinson’s disease.
Introduction
The pathogenesis of Parkinson’s disease involves 
various etiologies, which culminates in the degeneration 
of dopaminergic neurons in the substantia nigra of the 
midbrain and causes dysfunction of the nigro-striatal 
pathway and specific symptoms due to dopamine depletion 
[1, 2]. Th   erefore, pharmacological intervention using L-dopa, 
the precursor to dopamine, may effectively alleviate the 
symptoms. However, as the disease requires life-long L-dopa 
administration, the response is no longer satisfactory in the 
long term, as the remaining dopaminergic neurons continue 
to degenerate. Another approach is deep brain stimulation 
that is directed to the subthalamic nucleus or globus pallidus. 
This approach shows variable results but may relieve symp-Parkinson’s disease
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Stem Cell Therapy for Parkinson’s Disease
Stem cells have self-renewal capacity and multi-lineage 
plasticity. Therefore, they are a suitable source of various 
kinds of cells needed for cell therapy.   
To date, various studies have succeeded in diff  erentiating 
various kinds of stem cells into dopamine secreting neurons. 
Th   ese stem cells include human embryonic stem cells (hESCs), 
induced pluripotent stem cells, and mesenchymal stem cells 
(MSCs).
Embryonic stem cell therapy for Parkinson’s disease
Among all kinds of stem cells, ESCs have the most plas-
ticity, and can diff  erentiate into all types of cells, but they also 
tend to form tumors/teratomas upon grafting, which poses 
ethical problems. 
Various studies in vertebrate models have revealed that 
stepwise development of ESCs into dopaminergic neurons 
involves midbrain cell patterning using Wnt1 and fi  broblast 
growth factor 8 signaling [11], which directs the midbrain 
floor plate cells to express homeodomain transcription 
factors, i.e., Lmx1a and Msx1, that induce the proneural 
protein Ngn2 [12, 13]. Additionally, other homeodomain and 
paired-box transcription factors Pax2/5 and Engrailed 1 and 
2 are expressed [11, 14]. Furthermore, a glycoprotein named 
sonic hedgehog (SHH) from the midbrain floor plate cells 
joins the transcription factors to direct them into midbrain 
neural progenitors that adopt a dopaminergic fate and express 
Nurr1, ptx3, En-1, Foxa2, as well as dopaminergic genes that 
are essential for dopamine synthesis and metabolism [14-16].
During cell therapy for Parkinson’s disease, ESCs are step-
wise differentiated into neural stem cells (NSCs) or neural 
progenitor cells that may be transplanted into animal models 
or patients. Further differentiation into dopaminergic neu-
rons may be conducted either in vitro or occur in vivo aft  er 
transplantation.
Differentiation of ESCs into neural precursor cells (NPCs) 
and dopaminergic neurons: Effi   cient methods to diff  erentiate 
hESCs into midbrain-type neural precursor cells that can be 
expanded in vitro are available. NPCs can be differentiated 
further into dopa  minergic neurons [17-19]. To eliminate the 
tumorigenic potential, the NPCs should undergo multiple 
passages under differentiation-inducing conditions to 
eradicate the neuroepithelial rosettes that are potentially 
tumorigenic structures and to eliminate the persistent hESCs 
that can be proven by the absence of Oct3/4 bearing cells. 
Studies in rats have shown that grafted multiple-passaged 
NPCs do not form tumors or teratomas [18]. However, these 
cells show survival problems during expansion in vitro and 
aft  er transplantation in vivo [18], or loss of the dopaminergic 
neuron phenotype after transplantation [20]. Survival 
problems have been overcome by transgenic expression of 
Bcl-XL and SHH, without an increase in tumor formation 
[18]. Another ap  proach to overcome the survival problems 
was developed in rat NPCs using mutant Nurr1 (Nurr1AKT). 
Expression of mutant Nurr1 prevents its natural degradation 
and causes differentiation into dopaminergic neurons with 
better survival and a sustained phenotype, both in vitro and in 
vivo aft  er transplantation [20].
Differentiation of ESCs into NSCs and dopaminergic 
neurons: A study in a cynomolgus monkey Parkinson’s 
disease model showed that transplanting ESC-derived NSCs 
into the putamen restores dopamine function in the putamen 
12 weeks aft  er transplantation. Th   is result suggests dopamine 
release and differentiation of NSCs into dopaminergic 
neurons in vivo [21].
Induced pluripotent stem cell therapy for Parkinson’s 
disease
Induced pluripotent stem cells have similar properties 
to ESCs in terms of their pluripotency and tumor inducing 
capacity. They are suitable for cell therapy, as they can be 
generated from the patient’s own adult cells to prevent 
rejection and also will not pose ethical problems. However, 
methods should be developed to eliminate their tumor 
inducing property.
A method to differentiate a commercial human induced 
pluripotent stem (hiPS) cell line, namely IMR90 clone 4, into 
dopaminergic neuron progenitors is available. Furthermore, 
transplantation of these progenitors into a Parkinson’s disease 
rat model showed that these progenitors could survive for 
a long time, and many differentiated into dopaminergic 
neurons and integrated well into the surrounding tissue. 
However, nestin positive tumor-like cells were found at the 
transplant site. Therefore, efforts to purify the progenitors 
from contaminating undifferentiated hiPS cells are of great 
importance [22].
A patient-derived hiPS cell line has been developed for 
Parkinson’s disease due to a point mutation in α-synuclein 
(A53T). Th   e mutation was successfully repaired by zinc fi  nger 
nuclease genetic editing. The repaired hiPS differentiated 
into functional dopaminergic neurons [23]. Therefore, this Anat Cell Biol 2011;44:256-264 Jeanne Adiwinata Pawitan 258
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method provides an opportunity for a cure for Parkinson’s 
disease in the future due to a genetic point mutation.
MSCs in cell therapy for Parkinson’s disease
MSCs are multipotent stem cells of mesodermal origin 
that differentiate into various cells of connective tissue, 
skeletal muscle, and even neurons, when cultured under 
suitable differentiating conditions. Bone marrow-derived 
mesenchymal stem cells (BM-MSCs) were the first MSCs 
studied. Th   ey represent <0.01% of all nucleated bone marrow 
cells and are composed of myriads of adult stem cells [24]. 
MSCs from various tissues including adipose tissue has been 
reported. 
MSCs, either from bone marrow or adipose tissue, have 
several advantages. They can be taken from the patients 
them  selves for autotransplantation to avoid rejection, raise 
no ethical problems, and can be easily expanded. Moreover, 
the use of MSCs in Parkinson’s disease relies upon their 
immunosuppressive [25] and neuroprotective properties [26], 
as well as their ability to diff  erentiate into astrocyte-like cells 
and dopaminergic neurons [27-29].
Immunosuppressive property of MSCs: Th  e  immunosup-
pressive property of MSCs is mediated by inhibiting all of 
the cells that participate in the immune response cell-cell 
contact-dependent mechanism as well as by releasing various 
soluble factors [25]. This immuno  suppressive property is 
supposed to play a role inhibiting the infl  ammatory response 
and microglial activation; thus, preventing nigrostriatal 
dopaminergic neuron degeneration [30].
Neuroprotective property of MSCs: Th  e  neuroprotective 
property is mediated by a subpo  pulation of MSCs that 
produce various neurotrophic factors, such as brain-derived 
neurotrophic factor (BDNF), beta nerve growth factor, and 
GDNF [26]. These neurotrophic factors may play a role in 
protection, functional recovery, regeneration, and survival of 
remaining as well transplanted dopaminergic neurons and 
induce the proliferation and differentiation of endogenous 
NSCs [31].
Moreover, a laboratory has developed a protocol to induce 
BM-MSCs into neurotrophic factors-secreting cells (NTF-
SCs) that secrete BDNF and GDNF. Th   e NTF-SC conditioned 
medium shows marked protection in a Parkinson’s disease 
cellular model, and transplantation of the NTF-SCs into a rat 
model posterior to the damage resulted in migration of the 
transplanted cells into the damaged area and regeneration 
in the damaged dopaminergic nerve terminal system in the 
striatum [28].
Differentiation of MSCs into astrocyte-like cells: A 
method has been developed to differentiate BM-MSCs into 
GDNF, BDNF, and nerve growth factor-secreting astrocyte-
like cells using a special in vitro medium. Transplantation of 
these astrocyte-like cells into the striatum of a Parkinson’s 
disease rat model showed promising results. Additionally, a 
histological examination revealed survival of the transplanted 
cells and regeneration of the damaged dopaminergic nerve 
terminal network [27].
Diff  erentiation of MSCs into dopaminergic neurons: A 
standardized xeno-free in vitro protocol has been developed 
for proliferating and inducing a pure population of BM-
MSCs into a neuronal lineage that secretes dopamine. Trans-
plantation of these neuronal lineage cells into a Parkinson’s 
disease animal model showed significant improvement 3 
months aft  er transplantation [29].
Bone marrow stem cells (BM-SCs) in cell therapy for 
Parkinson’s disease
BM-SCs consist of various kinds of stem cells, including 
BM-MSCs and hematopoetic stem cells. They are a suitable 
source for cell therapy, although the procedure to obtain them 
is rather invasive and painful.
Transfection of tyrosine hydroxylase and a green fluore-
scent protein gene (GFP) containing plasmid into BM-SCs 
showed an 85% effi   ciency rate. Transfection was followed by 
culture in neuronal diff  erentiation medium. Injection of the 
cultured cells into the anterior horn of the lateral ventricle of 
a Parkinson’s disease rat model showed promising results 10 
days aft  er injection [32].
NSC therapy for Parkinson’s disease 
NSCs can be isolated from embryonic nerve tissue, and 
NSCs isolated from the subventricular zone of E14 rats form 
neurospheres in vitro. Transplanting NSCs into the substantia 
nigra pars compacta or striatum of Parkinson’s disease rat 
models resulted in survival of the transplanted cells [33].
Skin-derived stem cell therapy for Parkinson’s disease
Stem cells can be obtained either from dermis, which is 
a source of skin-derived precursors, or from hair follicles, 
which are a source of epidermal neural crest stem cells.
Skin-derived precursors: Skin-derived precursors are 
neu  ral crest-related stem cells that can be isolated from 
mammalian dermis. They differentiate into both neural Parkinson’s disease
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and mesodermal cell lineage cells. Therefore, skin-derived 
precursors are promising for use as an autologous stem cell 
source. 
A previous study used a synthetic von Hippel-Lindau 
peptide derived from the elongin BC-binding site that was 
conjugated to the protein transduction domain of the HIV-
TAT protein to facilitate entry into skin derived precursors. 
The results showed efficient generation of cells with dopa-
minergic neuronal and proneural markers. Furthermore, 
transplanting these cells into Parkinson’s disease model 
rats showed promising results, and that the cells generated 
dopaminergic neuron-like cells [34].
Epidermal neural crest stem cells: Epidermal neural crest 
stem cells (eNCSCs) are multi  potent neural crest cells that 
reside in the stem cell niche of hair follicles. Implantation of 
eNCSCs into infl  ammatory brain injured model rats resulted 
in differentiation of the cells into immature astrocytes and 
Schwann cells. As astrocytes secrete neurotrophic factors, 
eNCSCs may be a promising cell therapy candidate for 
Parkinson’s disease [35]. 
Other Cell Sources for Parkinson’s Disease 
Therapy 
Some cells other than stem cells are suitable for use as 
supportive cells for neurons, such as amniotic epithelial cells. 
These cells may be useful as alternative cell therapy sources 
for Parkinson’s disease.
Amniotic epithelial cell therapy for Parkinson’s 
disease
Amniotic epithelial cells are another source for cell therapy. 
However, donation of amniotic epithelial cell-containing 
amniotic fluid from pregnant women is needed to obtain 
these cells. Moreover, rejection problems may arise.
Amniotic epithelial cells secrete neurotrophic factors such 
as BDNF and neurotophin-3 and show promising results 
when transplanted into the striatum of Parkinson’s disease 
model rats. Additionally, transplanting amniotic epithelial 
cells into the lateral ventricle showed that the cells induced 
increases in dopamine and its metabolites in the striatum, 
expression of vimentin and nestin in the graft   aft  er 5 weeks, 
increases in tyrosine hydroxylase-positive cells in the 
substantia nigra aft  er 10 weeks, and a decrease in symptoms 
aft  er 2 weeks [36].
Retinal pigment epithelium (RPE) as cell therapy for 
Parkinson’s disease
RPE cells are L-dopa containing cells that can be isolated 
from the retina of human eyes. An in vitro and in vivo 
study on RPE in a rat model of Parkinson’s disease revealed 
improvement of the symptoms in vivo, which was due to 
several mechanisms, including secretion of neurotrophic 
factors, i.e., GDNF and BDNF, that protect dopaminergic 
neurons in vitro, differentiation of the cells into dopamine 
secreting cells in vitro, and survival of the cells in the striatum 
in vivo [37]. 
Commercial RPE cells that are attached to gelatin micro-
carriers are available as Spheramine (Bayer Schering Pharma 
AG, Berlin, Germany). The use of Spheramine without 
immunosuppression is claimed to be well tolerated and 
showed promising results in an open label study [37].
Fetal dopamine neurons as cell therapy for Parkin-
son’s disease
Fetal dopamine neurons can be obtained from the fetal 
midbrain. Fetal dopamine neurons transplanted into the 
striatum or both the striatum and substantia nigra of patients 
with Parkinson’s disease showed promising clinical results. 
Noninvasive brain imaging showed the presence of functional 
dopaminergic neurons at transplantation sites, and post 
mortem analyses 3-4 years after transplantation showed 
survival of the transplanted dopaminergic neurons and a 
mild immune response, though the patients received standard 
immune suppression for 6 months only. Moreover, the 
putamen was densely reinnervated with new dopaminergic 
fi  bers [38].
Cell Requirements for Cell Therapy in Parkin-
son’s Disease
Th   e cells for cell therapy should fulfi  ll certain requirements, 
including the identity of the cells and quality control during 
preparation.
Identity of the cells for cell therapy in Parkinson’s 
disease
Studies on various kinds of stem cells used different 
protocols to isolate and expand stem cells, as well as various 
markers to identify the cells, e.g., for NSCs, some studies used 
Mushashi-1, and other studies used nestin, or sox proteins. Anat Cell Biol 2011;44:256-264 Jeanne Adiwinata Pawitan 260
www.acbjournal.org http://dx.doi.org/10.5115/acb.2011.44.4.256
Whether the identity of NSCs from a particular study is the 
same or diff  erent from that of another study is unclear [39]. 
Moreover, nestin or a combination of nestin and Mushashi 
have also been used to identify human ESC-derived NPCs [18, 
19]. Th   erefore, the term NSC and NPC may refer to the same 
cell, and to conclude that NSCs and NPCs are the same cells 
requires further comparative studies.
Many kinds of cells or derivation of cells show promising 
results in in vitro and animal models. Th   erefore, the identity 
of the cells needs to be defined properly. Furthermore, to 
be translated into cell therapy for Parkinson’s disease, the 
protocols to generate the cells need to be standardized and 
tested in many laboratories to demonstrate that they are 
reproducible using xeno-free media. 
Quality control
Quality control includes the purity and production of cells 
according to good manufacturing practices. 
Purity: Cell therapy for Parkinson’s disease has used fetal 
ventral mesencephalic tissue, which contains dopaminergic 
neurons of mixed subtypes; therefore, the functional out-
comes were variable. The A9 subtype from the substantia 
nigra plays an important role in motor performance recovery 
compared to the A10 subtype from the ventral tegmental area 
[40]. In some cases, graft  -induced dyskinesia may occur, and 
this side eff  ect is supposed to be due to serotoninergic neuron 
contamination [41]. Th   erefore, cell purity should be assured. 
Good manufacturing practices: According to the US 
Food and Drug Administration, cell therapy products consist 
of two groups, the common “361 products,” which require 
good tissue practices, and the “351 products,” which require 
good manufacturing practices. Cell therapy products for 
Parkinson’s disease fall into the “351 category,” which include 
quality assurance, bioprocess monitoring control, automation, 
and product transportation [42].  
Mode and Site of Delivery
Various modes and sites of delivery for various kinds of 
cells have been reported, both in animal and in human studies 
with variable results (Table 1) [18, 32, 35, 43, 44].
Intravenous delivery
Various studies in animals and humans have shown 
that the pathogenesis of Parkinson’s disease involves an 
inflammatory reaction, which may play a role in neuron 
degene  ration. Furthermore, extensive reactive amoeboid 
micro  glial proliferation is found in the substantia nigra of 
patients with Parkinson’s disease [45, 46].
Intravenous administration of BM-MSCs and eNCSCs into 
rats results in homing of the cells to the infl  ammatory site in 
the corpus callosum, which is induced due to infl  ammatory 
injury [35]. Th   erefore, intravenous delivery may be eff  ective 
in Parkinson’s disease as well.
Moreover, MSCs are supposed to migrate to the damaged 
nigral area in Parkinson’s disease animal models due to the 
release of various chemokines, including stromal-cell derived 
factor-1α, by the damaged area [47, 48].
Delivery into the corpus callosum
Injection of cells into the corpus callosum distal to the 
inflammatory site results in migration of the cells toward 
the inflammatory site [35]. Therefore, the corpus callosum 
may be used as an alternative cell delivery site in Parkinson’s 
disease. 
Delivery into the anterior horn of the lateral ventricle
Injection of GFP-expressing BM-SCs into the anterior 
horn of the lateral ventricle of Parkinson’s disease rat models 
results in the presence of GFP expressing cells in the brain, 
suggesting migration of the injected cells through the ven-
Table 1. Various studies on cell therapy in animal models and patients
Cell type Amount of cells administered Mode of delivery Subject 
eNCSCs 50,000 in 5 μl Injection in corpus callosum  Rat model for infl  ammation [35]
eNCSCs 50,000 in 5 μl Intravenous Rat model for infl  ammation [35]
BM-SCs 50,000 in 5 μl Injection in corpus callosum  Rat model for infl  ammation [35]
BM-SCs 50,000 in 5 μl Intravenous  Rat model for infl  ammation [35]
TH gene transfected BM-SC 10
5 Injection into lateral horn of lateral ventricle Rat model for Parkinson’s disease [32]
hESCs derived NPCs 2.5×10
5/μl-3 μl (7.5×10
5) Injection into striatum  Rat model for Parkinson’s disease [18]
RPE cells in gelatin microcarriers 
  (Spheramine)
325,000 Implantation  into putamen (bilateral) Human, blinded safety and effi   cacy study [43, 44]
eNCSCs, epidermal neural crest stem cells; BM-SCs, bone marrow stem cells; hESCs, human embryonic stem cells; RPE, retinal pigment epithelium.Parkinson’s disease
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tricular wall along the nerve fi  bers [32].
Delivery into the striatum
Injections of Bcl-XL and SHH expressing hESC-derived 
NPCs have been performed at two sites in the striatum of 
Parkinson’s disease model rats, resulting in survival, pro-
liferation, and diff  erentiation of the injected cells into mature 
TH+ cells, extensive neurite outgrowth, and abundant mid-
brain-dopaminergic-neuron marker expression. Addi  tionally, 
reduced symptoms were observed in eight of 16 injected rats 
8 weeks aft  er the injection [18]. 
Another study on Parkinson’s disease model rats showed 
that route of delivery by injection of microcarriers-attached to 
RPE cells showed that the cells survived in the striatum and 
improved symptoms [2]. 
Delivery into the putamen
Several small open-label human studies on implanting 
micro  carriers attached to RPE cells in the putamen showed 
pro  mising results in symptom reduction. However, a double-
blind phase 2b clinical trial on implanting the cells into the 
bilateral putamen showed no efficacy beyond the placebo 
eff  ect [43]. A postmortem analysis of the patient showed that 
the estimated survival of the implanted cells after 6 months 
was only 0.036% [44].
 
Delivery into the substantia nigra
Transplanting enhanced green fl  uorescent protein (EGFP)-
expressing NSCs into the substantia nigra pars compacta or 
striatum of Parkinson’s disease rat models showed EGFP-
expressing NSCs at both sites at 1, 2, and 4 months post trans-
plantation. Moreover, the cells transplanted in the substantia 
nigra pars compacta dispersed, and a significant portion 
differentiated into tyrosine hydroxylase-positive neurons, 
whereas the cells transplanted into the striatum migrated 
ventrally and posteriorly toward the substantia nigra pars 
compacta and survived there for a long time [33]. Moreover, 
microtransplantation of dopamine neuroblasts into the 
substantia nigra of Parkinson’s disease model mice showed 
that the transplanted cells restored the damaged nigrostriatal 
pathway, increased expression of GDNF in the striatum, and 
improved symptoms [49].
Possible Side Eﬀ  ects
Possible side effects include tumor formation, migration 
of injected cells to non-target regions, immune rejection, side 
eff  ects of immunosuppressant use, graft  -induced dyskinesia, 
and mode of delivery-related adverse eff  ects. 
Tumor formation
Multifocal glioneuronal neoplasm was reported in a 
patient 4 years aft  er he received intracerebellar and intrathecal 
injections of human fetal NSCs. The neoplasm was derived 
from the injected cells and came from at least two donors [50].
Immune rejection and immunosuppressant use
Immune rejection of implanted allogeneic MSCs into the 
striatum has been reported in Parkinson’s disease model rats, 
irrespective of the immunosuppressive property of the MSCs. 
Though the immune response was insufficient to eliminate 
the MSCs by 22-24 days after implantation, no beneficial 
eff  ects were observed. Th   erefore, studies need to be conducted 
to clarify the immune response effect on cell survival and 
function [51]. Should an immunosuppressant be needed, the 
side eff  ects should be considered.
Graft   induced dyskinesia
Off phase graft-induced dyskinesia has been reported in 
some animal and human cell therapy studies for Parkinson’s 
disease using fetal tissue or cells. Th   e pathogenesis is supposed 
to involve serotonergic hyperinnervation in the striatum due 
to a proportion of serotonergic neurons that contaminated 
the graft  ed fetal cells [41, 52, 53]. 
Mode of delivery related side eff  ects
Mode of delivery related side eff  ects include hemorrhage 
and infection. Hemorrhage has been reported in a patient 
with Parkinson’s disease who received fetal ventral mid brain 
cell transplantation into the putamen through a canula. Th  e 
hemorrhage caused termination of the procedure after the 
first deposit, but the patient did not show any neurological 
defi  cits due the complications during transplantation [38].  
Eﬃ   cacy and Safety Studies 
Various kinds of cells show potential to differentiate into 
dopaminergic neurons or neurotrophic factor secreting Anat Cell Biol 2011;44:256-264 Jeanne Adiwinata Pawitan 262
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cells. Furthermore, some show effi   cacy in animal models for 
Parkinson’s disease, and some have been used in human trials. 
However, translation into therapy in humans requires effi   cacy 
and safety assurance. 
Th  erefore,  effi   cacy and safety studies need to be conducted 
in animal models for the various kinds of cells to understand 
what happens to the cells after transplantation, their survi-
val, migration, and differentiation into desired cells in the 
Parkinson’s disease model environment. Integration of trans-
planted cells in a degenerated system might be diffi   cult, and 
integration into the existing neuronal pathway needs to be 
confi  rmed. 
It is important to test the effi   cacy and safety of various cell 
delivery routes to identify the most effi   cient route, the number 
of cells to be delivered, and to detect possible side eff  ects that 
may arise. 
For human trials, tracking injected cells using noninvasive 
brain imaging is of great importance to monitor the injected 
cells in term of their growth, their migration either to desired 
or undesired location, as well as their survival and function 
[54].
Postmortem analyses on transplanted fetal mesencephalic 
neurons in patients with Parkinson’s disease revealed confl  ic-
ting results in term of the appearance of Lewy bodies and 
α-synuclein positivity [9, 55 56]. Th  ese  confl  icting results may 
be due to the pathogenesis that underlies the dopaminergic 
neuronal loss in Parkinson’s disease. As Lewy bodies and 
α-synuclein represent one of the pathological conditions, 
their appearance in transplanted neurons suggest that 
the pathological microenvironment may lead to ongoing 
neuronal death, which may aff  ect transplanted cells [56, 57].
Therefore, studies need to be conducted to reveal the 
exact cause and microenvironmental pathology in various 
kinds of Parkinson’s disease. Th   is knowledge may be useful to 
modulate the microenvironment to increase efficacy and to 
obtain a sustainable eff  ect from cell therapy in the future.
Conclusion 
Various kinds of cells are suitable for cell therapy in 
patients with Parkinson’s disease. However, safety and effi   cacy 
studies need to be conducted followed by standardized 
procedures for each type of cell, mode and site of delivery, and 
type of Parkinson’s disease. In addition, modulation of the 
microenvironment may lead to a sustainable therapeutic eff  ect.
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